This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Scandinavian Life Science Days | |
|---|---|
| Name | Scandinavian Life Science Days |
| Status | Active |
| Genre | Conference |
| Frequency | Annual |
| Location | Scandinavia |
| First | 1990s |
| Organizer | Industry and academia |
Scandinavian Life Science Days
Scandinavian Life Science Days is an annual biotechnology and pharmaceutical conference held in Scandinavia that convenes leaders from industry, academia, investment, and policy. The meeting attracts participants from biotechnology firms, pharmaceutical companies, venture capital firms, research institutes, technology transfer offices, and regulatory agencies to discuss drug discovery, diagnostics, and digital health. The event is noted for combining scientific presentations with business development and networking forums that link translational research to commercialization.
Scandinavian Life Science Days brings together delegates from Novo Nordisk, AstraZeneca, Roche, Pfizer, Novo Holdings, Ericsson, Biogen, Merck Group, Johnson & Johnson, GSK, Sanofi, Bayer, Novartis, Amgen, Takeda Pharmaceutical Company, Eli Lilly and Company, Huawei, Siemens Healthineers, Illumina, Thermo Fisher Scientific, GE Healthcare, Boston Scientific, Medtronic, AbbVie, Boehringer Ingelheim, Shire (Takeda), Orion Corporation, Sobi, Recipharm, GE Healthcare Life Sciences, AstraZeneca R&D, Karolinska Institutet, University of Copenhagen, University of Oslo, University of Helsinki, Uppsala University, Chalmers University of Technology, KTH Royal Institute of Technology, Lund University, Aalto University, Stockholm University, DTU (Technical University of Denmark), Norwegian University of Science and Technology, Technical University of Munich, Imperial College London, Harvard University, Stanford University, MIT, Yale University, Columbia University, Cambridge University, Oxford University, Princeton University for cross-sector dialogue and deal-making.
The meeting traces roots to regional biotech gatherings in the 1990s and early 2000s that involved EIT Health, European Investment Bank, European Commission, Nordic Innovation, NordForsk, Innovation Norway, Vinnova, Tekes, Business Sweden, Invest in Denmark, Enterprise Ireland, Swedish Agency for Economic and Regional Growth, Danish Agency for Science and Higher Education. Early iterations featured panels with representatives from European Medicines Agency, U.S. Food and Drug Administration, World Health Organization, Organisation for Economic Co-operation and Development, World Intellectual Property Organization, and national funding bodies. Over time the conference evolved alongside landmark events such as the Human Genome Project, the rise of next-generation sequencing, the emergence of CAR T cell therapies, and advances in CRISPR-Cas9 genome editing, reflecting translational shifts similar to initiatives at Wellcome Trust and Bill & Melinda Gates Foundation.
The event is typically administered by a consortium of industry trade groups, academic institutes, and regional development agencies including Swedish Medtech, Danish MedTech, Norwegian Biotech Industry Organization, Bioindustria, European Federation of Pharmaceutical Industries and Associations, The Association of the British Pharmaceutical Industry, Invest Sweden, Innovation Norway, Finnish Funding Agency for Technology and Innovation. Governance structures often include advisory boards with leaders from European Investment Fund, NordicBIO, Scandinavian Venture Network, SVCA (Swedish Venture Capital Association), NVCA, PitchBook, Life Science Sweden, SIGHT VENTURES, Novo Seeds, SEED Capital. Program committees have included scientists and executives affiliated with Karolinska University Hospital, Rigshospitalet, Oslo University Hospital, Helsinki University Hospital.
Programmes cover translational research topics such as biopharmaceuticals, immuno-oncology, neuroscience, cardiovascular disease, metabolic disease, rare disease, precision medicine, companion diagnostics, liquid biopsy, biomarkers, single-cell sequencing, synthetic biology, gene therapy, cell therapy, RNA therapeutics, antibody–drug conjugates, drug delivery, pharmacogenomics, real-world evidence, health economics and outcomes research, digital therapeutics, wearable technology, artificial intelligence in drug discovery, machine learning, blockchain in healthcare and regulatory pathways tied to European Medicines Agency decisions. Sessions frequently mirror thematic tracks seen at BIO International Convention, European Society of Cardiology Congress, American Society of Clinical Oncology Annual Meeting, DIA Global Annual Meeting, JP Morgan Healthcare Conference, EMBO symposia, and Cold Spring Harbor Laboratory meetings.
Attendees typically include chief executives, chief scientific officers, chief medical officers, investors, technology transfer officers, and principal investigators from institutions such as Max Planck Society, Fraunhofer Society, Erasmus University Rotterdam, Vanderbilt University Medical Center, Mayo Clinic, Cleveland Clinic, Karolinska Institutet, University College London, The Francis Crick Institute, Institut Pasteur, CNRS, INSERM, Helmholtz Association, European Molecular Biology Laboratory, Wellcome Sanger Institute, Broad Institute, Cold Spring Harbor Laboratory, Sanger Centre, European Society for Medical Oncology. Attendance numbers vary, drawing delegates from multinational firms like Goldman Sachs, J.P. Morgan, Perseus Group, SVB Financial Group, BP Ventures, BlackRock and venture funds such as Sequoia Capital, Index Ventures, Accel Partners, Balderton Capital, Atomico, HealthCap, 3i Group, Novartis Venture Fund, Pfizer Ventures.
The conference acts as a platform for partnerships and licensing deals involving companies like Recipharm, Idogen, BioInvent International, Oncopeptides, CureVac, Genmab, MorphoSys, Ferring Pharmaceuticals, Alvotech, Olink, Sartorius, CellaVision, PerkinElmer, Waters Corporation, Agilent Technologies, Qiagen, Takara Bio, Zymo Research, NanoString Technologies, PacBio, Becton Dickinson. Collaborative initiatives announced at the event have linked regional life science clusters such as Medicon Valley, BioGro, Medicon Village, Science Park Aarhus, Oulu Health with international consortia including Innovative Medicines Initiative, Horizon Europe, IMI, EU Horizon 2020 and philanthropic partnerships with Gates Foundation-supported programs.
The conference often features awards and pitch competitions judged by panels including representatives from European Innovation Council, Nordic Innovation Prize, Red Herring Top 100, Deloitte Fast 50, EY Entrepreneur Of The Year, MedTech Innovator, Startupbootcamp Life Sciences, MassChallenge, Hello Tomorrow and regional investor groups like Swedish Private Equity & Venture Capital Association, Danish Growth Fund. Winners have included Scandinavian startups later acquired or partnered with firms such as AstraZeneca, Novo Nordisk, Roche and have received follow-on funding from Index Ventures, Sequoia Capital, Temasek Holdings, SoftBank Vision Fund.
Category:Conferences in Scandinavia